MedTrace Logo

TiLE (Time Lapse Eeva) Clinical Trial

NCT02417441 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 976

Last updated 2020-01-30

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to explore the added value of adjunctive use of Early Embryo Viability Assessment (Eeva) with morphological grading in identifying optimal embryos for transfer.

Conditions

Interventions

DEVICE

Eeva

Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Medical Responsible · Merck KGaA, Darmstadt, Germany

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-29
Primary Completion
2017-02-09
Completion
2017-02-09

Countries

  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Norway
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02417441 on ClinicalTrials.gov